ATE187964T1 - N-substituierte chinolinderivate, verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen - Google Patents
N-substituierte chinolinderivate, verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungenInfo
- Publication number
- ATE187964T1 ATE187964T1 AT92400294T AT92400294T ATE187964T1 AT E187964 T1 ATE187964 T1 AT E187964T1 AT 92400294 T AT92400294 T AT 92400294T AT 92400294 T AT92400294 T AT 92400294T AT E187964 T1 ATE187964 T1 AT E187964T1
- Authority
- AT
- Austria
- Prior art keywords
- production
- pharmaceutical compositions
- compositions containing
- containing same
- medicinal products
- Prior art date
Links
- -1 N-SUBSTITUTED QUINOLINE Chemical class 0.000 title abstract 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000002252 acyl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- IKNZBNHVVQIRTO-UHFFFAOYSA-N 2h-tetrazole-5-carboxylic acid Chemical compound OC(=O)C=1N=NNN=1 IKNZBNHVVQIRTO-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000005110 aryl thio group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 abstract 1
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000003396 thiol group Chemical class [H]S* 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/28—Cinnolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9101372A FR2672597B1 (fr) | 1991-02-07 | 1991-02-07 | Nouveaux derives n-substitues de la quinoleine, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant. |
| FR9110433A FR2680511B1 (fr) | 1991-08-20 | 1991-08-20 | Derives n-substitues de la quinoleine, leur procede de preparation, intermediaires obtenus, leur application comme medicaments et les compositions les renfermant. |
| FR9114282A FR2684671B1 (fr) | 1991-11-20 | 1991-11-20 | Nouveaux derives de la quinoleine, leur procede de preparation et intermediaires et leur application a titre de medicaments. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE187964T1 true ATE187964T1 (de) | 2000-01-15 |
Family
ID=27252397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT92400294T ATE187964T1 (de) | 1991-02-07 | 1992-02-05 | N-substituierte chinolinderivate, verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US5985894A (enExample) |
| EP (1) | EP0498721B1 (enExample) |
| JP (1) | JP3599350B2 (enExample) |
| KR (1) | KR100334208B1 (enExample) |
| CN (1) | CN1064076A (enExample) |
| AT (1) | ATE187964T1 (enExample) |
| BR (1) | BR9200432A (enExample) |
| CA (1) | CA2060843A1 (enExample) |
| CZ (1) | CZ291217B6 (enExample) |
| DE (1) | DE69230449T2 (enExample) |
| DK (1) | DK0498721T3 (enExample) |
| ES (1) | ES2141098T3 (enExample) |
| FI (1) | FI103574B1 (enExample) |
| GR (1) | GR3032711T3 (enExample) |
| HU (1) | HUT64524A (enExample) |
| IE (1) | IE920395A1 (enExample) |
| IL (1) | IL100555A (enExample) |
| MA (1) | MA22410A1 (enExample) |
| NZ (1) | NZ241546A (enExample) |
| OA (1) | OA09528A (enExample) |
| PL (1) | PL169672B1 (enExample) |
| PT (1) | PT498721E (enExample) |
| RU (1) | RU2125047C1 (enExample) |
| TW (1) | TW214554B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1625192A (en) * | 1991-05-31 | 1992-12-03 | Zeneca Limited | Heterocyclic derivatives |
| GB9121727D0 (en) * | 1991-10-14 | 1991-11-27 | Ici Plc | Heterocyclic compounds |
| JPH05310732A (ja) * | 1992-03-12 | 1993-11-22 | Mitsubishi Kasei Corp | シンノリン−３−カルボン酸誘導体 |
| IT1312107B1 (it) * | 1999-05-14 | 2002-04-04 | Umberto Cornelli | Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile |
| SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| KR20030027094A (ko) * | 2000-08-29 | 2003-04-03 | 야마노우치세이야쿠 가부시키가이샤 | 신규 에스테르 또는 아미드 유도체 |
| EG24415A (en) * | 2002-03-07 | 2009-05-25 | Novartis Ag | Quinoline derivatives |
| AU2003270446A1 (en) * | 2002-09-25 | 2004-04-19 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating alzheimer's disease and dementias of vascular origin |
| US7176220B2 (en) | 2002-11-20 | 2007-02-13 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| US7531554B2 (en) | 2004-05-20 | 2009-05-12 | Japan Tobacco Inc. | 4-oxoquinoline compound and use thereof as HIV integrase inhibitor |
| US8633219B2 (en) | 2004-05-21 | 2014-01-21 | Japan Tobacco Inc. | Combination therapy |
| US20070071679A1 (en) * | 2005-09-29 | 2007-03-29 | Hilakivi Ilkka T | Methylamine risks and treatment of hyperactivity, depression, and alcoholism with epinephrine-N-quinolines |
| EP1978960A4 (en) * | 2006-02-01 | 2009-12-02 | Japan Tobacco Inc | USE OF 6- (3-CHLORO-2-FLUORBENZYL) -1 - [(2S) -1-HYDROXY-3-METHYLBUTAN-2-YL [-7-METHOXY-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXYLIC ACID OR SALT THEREOF FOR THE TREATMENT OF RETROVIRUS INFECTION |
| JP4669040B2 (ja) | 2006-03-06 | 2011-04-13 | 日本たばこ産業株式会社 | ４−オキソキノリン化合物の製造方法 |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| GB0716532D0 (en) | 2007-08-24 | 2007-10-03 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| EP3023426A1 (en) | 2008-07-17 | 2016-05-25 | Critical Outcome Technologies, Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
| TWI492943B (zh) * | 2008-12-05 | 2015-07-21 | 大塚製藥股份有限公司 | 喹啉酮化合物及藥學組成物（二） |
| WO2011120153A1 (en) * | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| PL3004138T3 (pl) | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2555943A (en) * | 1947-06-28 | 1951-06-05 | Sterling Drug Inc | Dihalo-4-(aliphatic tertiaryamino-alkylamino)quinolines |
| US3002001A (en) * | 1958-04-03 | 1961-09-26 | Sterling Drug Inc | 4-alkylimino-1-[aromatic-(lower - alkyl)]-1,4-dihydroquinolines and their preparation |
| GB1419789A (en) * | 1972-08-02 | 1975-12-31 | Pfizer | 2-trifluoromethyl-4-quinolinols |
| GB1432649A (enExample) * | 1973-09-07 | 1976-04-22 | Ici Ltd | |
| GB1472767A (en) * | 1974-11-07 | 1977-05-04 | Ici Ltd | Process for the preparation of cinnoline derivatives |
| FR2377400A2 (fr) * | 1977-01-18 | 1978-08-11 | Roussel Uclaf | Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament |
| NZ193167A (en) * | 1979-03-27 | 1984-08-24 | Boots Co Plc | Quinoline derivatives and pharmaceutical compositions |
| JPS58219166A (ja) * | 1982-06-14 | 1983-12-20 | Nippon Shinyaku Co Ltd | ４−キノロン誘導体 |
| SU1421374A1 (ru) * | 1987-03-31 | 1988-09-07 | Предприятие П/Я М-5671 | Устройство дл регенерации мелкопористых фильтроэлементов |
| US4920131A (en) * | 1987-11-03 | 1990-04-24 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene D4 |
| US4880804A (en) * | 1988-01-07 | 1989-11-14 | E. I. Du Pont De Nemours And Company | Angiotensin II receptor blocking benzimidazoles |
| US5081121A (en) * | 1988-05-24 | 1992-01-14 | Tatsushi Osawa | 4(1h)-quinolone derivatives |
| US4918081A (en) * | 1988-06-20 | 1990-04-17 | Rorer Pharmaceutical Corp. | Quinoline derivatives and use thereof as antagonists of leukotriene d4 |
| US5064825A (en) * | 1989-06-01 | 1991-11-12 | Merck & Co., Inc. | Angiotensin ii antagonists |
| US4959363A (en) * | 1989-06-23 | 1990-09-25 | Sterling Drug Inc. | Quinolonecarboxamide compounds, their preparation and use as antivirals. |
| ATE117294T1 (de) * | 1989-08-11 | 1995-02-15 | Ici Plc | Chinolin-derivate, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel. |
| CA2037630C (en) * | 1990-03-07 | 2001-07-03 | Akira Morimoto | Nitrogen-containing heterocylic compounds, their production and use |
| US5157040A (en) * | 1991-04-05 | 1992-10-20 | Merck & Co., Inc. | Substituted quinolines as angiotensin ii antagonists |
| US5162325A (en) * | 1991-05-07 | 1992-11-10 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted benzyl element |
| US5162340A (en) * | 1991-05-10 | 1992-11-10 | Merck & Co., Inc. | Substituted 1-(2h)-isoquinolinones bearing acidic functional groups as angiotensin ii antagonists |
-
1991
- 1991-12-30 IL IL10055591A patent/IL100555A/xx not_active IP Right Cessation
-
1992
- 1992-02-04 MA MA22697A patent/MA22410A1/fr unknown
- 1992-02-04 JP JP04759492A patent/JP3599350B2/ja not_active Expired - Fee Related
- 1992-02-05 EP EP92400294A patent/EP0498721B1/fr not_active Expired - Lifetime
- 1992-02-05 DK DK92400294T patent/DK0498721T3/da active
- 1992-02-05 ES ES92400294T patent/ES2141098T3/es not_active Expired - Lifetime
- 1992-02-05 AT AT92400294T patent/ATE187964T1/de not_active IP Right Cessation
- 1992-02-05 PT PT92400294T patent/PT498721E/pt unknown
- 1992-02-05 DE DE69230449T patent/DE69230449T2/de not_active Expired - Fee Related
- 1992-02-06 FI FI920504A patent/FI103574B1/fi active
- 1992-02-06 KR KR1019920001715A patent/KR100334208B1/ko not_active Expired - Fee Related
- 1992-02-06 HU HU9200367A patent/HUT64524A/hu unknown
- 1992-02-06 IE IE039592A patent/IE920395A1/en unknown
- 1992-02-06 RU SU5010859A patent/RU2125047C1/ru active
- 1992-02-07 CN CN92100765A patent/CN1064076A/zh active Pending
- 1992-02-07 CA CA002060843A patent/CA2060843A1/fr not_active Abandoned
- 1992-02-07 BR BR929200432A patent/BR9200432A/pt not_active Application Discontinuation
- 1992-02-07 OA OA60146A patent/OA09528A/fr unknown
- 1992-02-07 CZ CS1992357A patent/CZ291217B6/cs not_active IP Right Cessation
- 1992-02-07 NZ NZ241546A patent/NZ241546A/en unknown
- 1992-02-07 PL PL92293414A patent/PL169672B1/pl unknown
- 1992-02-18 TW TW081101181A patent/TW214554B/zh active
-
1997
- 1997-11-04 US US08/964,182 patent/US5985894A/en not_active Expired - Fee Related
-
2000
- 2000-02-18 GR GR20000400410T patent/GR3032711T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2141098T3 (es) | 2000-03-16 |
| IL100555A (en) | 2000-08-31 |
| HUT64524A (en) | 1994-01-28 |
| OA09528A (fr) | 1992-11-15 |
| BR9200432A (pt) | 1992-10-13 |
| JP3599350B2 (ja) | 2004-12-08 |
| TW214554B (enExample) | 1993-10-11 |
| IE920395A1 (en) | 1992-08-12 |
| FI920504A7 (fi) | 1992-08-08 |
| FI103574B (fi) | 1999-07-30 |
| EP0498721B1 (fr) | 1999-12-22 |
| CN1064076A (zh) | 1992-09-02 |
| EP0498721A1 (fr) | 1992-08-12 |
| DK0498721T3 (da) | 2000-06-26 |
| PL169672B1 (pl) | 1996-08-30 |
| RU2125047C1 (ru) | 1999-01-20 |
| CZ291217B6 (cs) | 2003-01-15 |
| MA22410A1 (fr) | 1992-10-01 |
| GR3032711T3 (en) | 2000-06-30 |
| KR920016432A (ko) | 1992-09-24 |
| CA2060843A1 (fr) | 1992-08-08 |
| IL100555A0 (en) | 1992-09-06 |
| FI920504A0 (fi) | 1992-02-06 |
| DE69230449D1 (de) | 2000-01-27 |
| DE69230449T2 (de) | 2000-08-03 |
| HU9200367D0 (en) | 1992-04-28 |
| FI103574B1 (fi) | 1999-07-30 |
| NZ241546A (en) | 1995-03-28 |
| PL293414A1 (en) | 1993-05-04 |
| CZ35792A3 (en) | 1993-10-13 |
| PT498721E (pt) | 2000-04-28 |
| JPH04360872A (ja) | 1992-12-14 |
| US5985894A (en) | 1999-11-16 |
| KR100334208B1 (ko) | 2002-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69230449D1 (de) | N-substituierte Chinolinderivate, Verfahren zur Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammensetzungen | |
| DE58907280D1 (de) | 7-Substituierte Derivate der 3,5-Dihydroxyhept-6-insäure, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel, sowie Zwischenprodukte. | |
| ATE144503T1 (de) | Thiazolidin-2,4-dionderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen | |
| ATE205832T1 (de) | Stickstoff enthaltende bicyclische verbindungen, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel und diese enthaltende zusammensetzungen | |
| ATE127452T1 (de) | Poly-4-aminopyrrole-2-carboxamide derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
| ATE217310T1 (de) | Bicyclische pyridinderivate, verfahren zu ihrer herstellung, zwischenprodukte, ihre anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen | |
| ATE140218T1 (de) | Phenylimidazolidine, verfahren zu deren herstellung, deren anwendung als arzneimittel und diese enthaltende pharmazeutische zusammenstellungen | |
| ATE199250T1 (de) | Sulfonamidocarbonylpyridin-2-carbonsäureamide und ihre verwendung als arzneimittel | |
| ATE170510T1 (de) | 3-(hydroxybenzylidenyl)-indolin-2-one und diese enthaltende arzneimittel | |
| DE59401924D1 (de) | Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel | |
| DE59000750D1 (de) | Arzneimittel, enthaltend di-tert.-butylhydroxyphenyl-derivate sowie neue derivate. | |
| NO945034L (no) | Derivater i vitamin D-serien modifisert ved 20-stilling, en fremg. for frems. av slike derivater, mellomprodukter anvendt ved fremg., farmasöytiske preparater inneholdende derivatene og deres anvendelse ved frems. av legemidler | |
| ATE62683T1 (de) | Labdanderivate, verfahren zu deren herstellung und deren verwendung als arzneimittel. | |
| ATE172461T1 (de) | Chinoxalin-2,3(1h,4h)-dione als arzneimittel | |
| DE3869173D1 (de) | Amino 5,6,7,8-tetrahydronaphtho(2,3b)furanderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
| DE3782347D1 (de) | Hetaryl-oxy-beta-carbolinderivate, ihre herstellung und verwendung als arzneimittel. | |
| ATE150745T1 (de) | 22-en-25-oxa-derivate in der vitamin d-reihe, verfahren zu ihrer herstellung, diese derivate enthaltenen pharmazeutische präparate sowie deren verwendung als arzneimittel | |
| ATE18221T1 (de) | (1-arylcyclobutyl)(heterocyclyl)methylaminderivate, ihre herstellung und ihre verwendung als arzneimittel. | |
| DK0564358T3 (da) | 3-aminochroman-spiro-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende sådanne | |
| ATE128968T1 (de) | 2-cyano-2-hydroxypropenamidederivate, verfahren zu ihrer herstellung ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen. | |
| DE3678478D1 (de) | Beta-lactam-antibiotika, verfahren zur herstellung und ihre verwendung als arzneimittel. | |
| DE3678470D1 (de) | Neue 3-pyridylmethylnaphthylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel. | |
| ATE13669T1 (de) | 4-aryloxy-3-phenylpiperidin-derivate, zwischenprodukte, verfahren zur herstellung solcher verbindungen und ihre verwendung als arzneimittel. | |
| DE3879234D1 (de) | Substituierte 3-phenyl-7h-thiazolo(3,2 -b) (1,2,4)triazin-7-one, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung, sowie einige bei der herstellung der genannten verbindungen gebildete zwischenprodukte. | |
| ATE189810T1 (de) | Eine trifluormethylsulfonylphenyl- oder trifluormethylsulfinylphenylgruppe enthaltende 2- cyan-3-hydroxy-propenamidderivate, verfahren zu ihrer herstellung, ihre anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |